Telix Expands U.S. Radiopharmaceutical Production with IBA Cyclone KIUBE Order
Event summary
- Telix ordered four IBA Cyclone® KIUBE cyclotrons for U.S. radiopharmacy sites, signed in late 2025.
- Systems will enable in-house production of isotopes like Gallium-68 and Zirconium-89 for cancer care.
- Each cyclotron includes ARTMS' QUANTM® Irradiation System for cGMP-compliant radio-metal production.
- Deal strengthens IBA's position in radiopharmaceutical production solutions market.
The big picture
This deal represents a strategic move to strengthen U.S. manufacturing capabilities for radiopharmaceuticals, addressing growing demand for precision oncology tools. The integration of advanced cyclotron technology with Telix's distribution network positions both companies to capture market share in the expanding theranostics sector. The $1.2 billion radiopharmaceuticals market is projected to grow at 11.3% CAGR through 2030, driven by increasing cancer prevalence and technological advancements.
What we're watching
- Supply Chain Impact
- How Telix's localized production will affect reliance on external isotope suppliers.
- Technological Integration
- Whether the combination of IBA cyclotrons and ARTMS technology can sustain high-yield production.
- Market Expansion
- The pace at which this collaboration can scale to meet rising demand for theranostic solutions.
Related topics